EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Matched-samples comparison of intramuscular versus vaginal progesterone for luteal phase support after in vitro fertilization and embryo transfer



Matched-samples comparison of intramuscular versus vaginal progesterone for luteal phase support after in vitro fertilization and embryo transfer



Fertility and Sterility 91(6): 2445-2450



To evaluate vaginal compared to intramuscular (IM) progesterone supplementation for luteal phase support after in vitro fertilization and embryo transfer (IVF-ET). Retrospective matched-samples comparative study. Private infertility center. Two hundred forty patients undergoing IVF-ET. Patients received either vaginal progesterone supplementation in the form of Endometrin 100 mg twice a day (n = 12), Endometrin 100 mg three times a day (n = 11), or Crinone 8% gel 90 mg every day (n = 17), or 50 mg every day IM progesterone in oil (n = 200). Clinical intrauterine pregnancy rates, pregnancy loss, and live birth rates. Among patients using vaginal progesterone, there were no statistically significant differences in patient characteristics and clinical outcomes, regardless of the type of vaginal progesterone used. There were no differences in outcomes between the vaginal and IM progesterone treatment groups. There were 20 pregnancies (50.0%) among patients treated with vaginal progesterone and 103 pregnancies (51.5%) among matched IM progesterone patients. The live birth rates were 47% in the IM versus 47.5% in the vaginal progesterone groups. There were no statistically significant differences in miscarriage rates between groups. There are no significant differences in treatment outcomes between vaginal and IM progesterone supplementation, yielding similar clinical pregnancy, miscarriage, and live birth rates.

(PDF emailed within 0-6 h: $19.90)

Accession: 054267569

Download citation: RISBibTeXText

PMID: 18555224

DOI: 10.1016/j.fertnstert.2008.03.072



Related references

Intramuscular versus vaginal administration of progesterone for luteal phase support after in vitro fertilization and embryo transfer. A comparative randomized study. Clinical and Experimental Obstetrics & Gynecology 26(3-4): 203-206, 2000

Intramuscular progesterone (Gestone) versus vaginal progesterone suppository (Cyclogest) for luteal phase support in cycles of in vitro fertilization-embryo transfer: patient preference and drug efficacy. Fertility Research and Practice 3: 17-17, 2017

Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization-embryo transfer. Fertility and Sterility 93(2): 554-569, 2010

A comparison of luteal phase support in graduated estradiol/progesterone replacement cycles using intramuscular progesterone alone versus combination with vaginal suppositories on outcome following frozen embryo transfer. Clinical and Experimental Obstetrics & Gynecology 32(2): 93-94, 2005

Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization-embryo transfer cycles: a prospective randomized study. Fertility and Sterility 94(7): 2596-2599, 2011

Intramuscular progesterone versus 8% Crinone vaginal gel for luteal phase support for day 3 cryopreserved embryo transfer. Fertility and Sterility 98(6): 1464-1469, 2013

A comparison of luteal phase support in graduated estradiol/progesterone replacement cycles using intramuscular progesterone alone vs combination with vaginal suppositories on outcome following frozen embryo transfer. Fertility & Sterility 81(Suppl 3): S30, April, 2004

Phase III trial of 8% vaginal progesterone gel for luteal phase support in Japanese women undergoing in vitro fertilization and fresh embryo transfer cycles. Reproductive Medicine and Biology 16(1): 52-57, 2017

Phase III trial of 8% vaginal progesterone gel for luteal phase support in Japanese women undergoing in vitro fertilization and fresh embryo transfer cycles. Reproductive Medicine and Biology 16(1): 52-57, 2017

Luteal phase support for frozen embryo transfer cycles: intramuscular or vaginal progesterone?. Fertility and Sterility 101(3): 627-628, 2014

Luteal-phase support in stimulated cycles in an in vitro fertilization/embryo transfer program: progesterone versus human chorionic gonadotropin. Journal of in Vitro Fertilization and Embryo Transfer 5(2): 81-84, 1988

Vaginal (Crinone 8%) gel vs. intramuscular progesterone in oil for luteal phase support in in vitro fertilization: a large prospective trial. Fertility and Sterility 97(2): 344-348, 2012

Chorionic gonadotropin support of the luteal phase following in vitro fertilization and embryo transfer. Randomized comparison with oral progesterone in protocols using triptoreline. Presse Medicale 18(10): 539-539, 1989

Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study. Fertility and Sterility 101(1): 112-119.E3, 2014

Effects of early luteal-phase vaginal progesterone supplementation on the outcome of in vitro fertilization and embryo transfer. Gynecological Endocrinology 24(12): 674-680, 2009